Ferdinandos Skoulidis

The University of Texas MD Anderson Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 24 papers. Top paper: “Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial”.

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-001001

N/A

4.9DataRank · unranked

289 citations

Hari Menon, Dawei Chen, Vivek Verma, Chad Tang, Mehmet Altan +12 more

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Nature Medicine(2023)10.1038/s41591-022-02189-0

N/A

4.1DataRank · unranked

213 citations

Cheuk Hong Leung, Annikka Weissferdt, Apar Pataer, Brett W. Carter, Myrna C. B. Godoy +52 more

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1420

N/A

0.787DataRank · unranked

189 citations

Haniel A. Araújo, Giuseppe Lamberti, Alissa J. Cooper, Neal S. Akhave, Teng Zhou +61 more

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Nature(2024)10.1038/s41586-024-07943-7

N/A

0.769DataRank · unranked

168 citations

Haniel A. Araújo, Minh Truong, Yu Qian, Xin Sun, Ana Galán‐Cobo +95 more

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

The Lancet Digital Health(2023)10.1016/s2589-7500(23)00082-1

N/A

0.708DataRank · unranked

111 citations

Lingzhi Hong, Muhammad Aminu, Natalie I. Vokes, Pingjun Chen, Morteza Salehjahromi +44 more

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.07.005

N/A

0.701DataRank · unranked

106 citations

Joao V. Alessi, Arielle Elkrief, Xinan Wang, Alessio Cortellini, Y Y Li +27 more

Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma

Annals of Oncology(2023)10.1016/j.annonc.2023.04.514

N/A

0.510DataRank · unranked

29 citations

Christine Lydon, Emily S. Chambers, Lynette M. Sholl, Mizuki Nishino, Ferdinandos Skoulidis +8 more

Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.11.020

N/A

0.494DataRank · unranked

26 citations

Robyn Du, Nathaniel J. Myall, Whitney E. Lewis, Natalie Uy, Lingzhi Hong +22 more

Advances in Lung Cancer Basic and Translational Research in 2025 – Overview and Perspectives Focusing on NSCLC

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.05.024

N/A

0.406DataRank · unranked

14 citations

Triparna Sen, Montse Sánchez‐Céspedes, Sandra Ortiz‐Cuaran, Yohan Bossé, Floris Dammeijer +23 more

A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9060

N/A

0.208DataRank · unranked

3 citations

Mary W. Redman, Jennifer M. Suga, Tareq Al Baghdadi, John L. Villano, Sarah B. Goldberg +6 more

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy

Cancer Research(2025)10.1158/0008-5472.can-25-0998

N/A

0.104DataRank · unranked

1 citations

Soumyadip Sahu, Minjie Zhang, Ayushi S. Patel, Ke Geng, Reshmee Bhattacharya +47 more

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002891

N/A

0DataRank · unranked

292 citations

Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bāra, Vincent K. Shen +33 more

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.10.013

N/A

0DataRank · unranked

374 citations

Kathryn C. Arbour, W. Marston Linehan, Amir Vajdi, Natalie I. Vokes, Lingzhi Hong +28 more

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Nature(2021)10.1038/s41586-021-03898-1

N/A

0DataRank · unranked

459 citations

Xiuning Le, R. S. K. Vijayan, J. Kevin Hicks, Simon Heeke, Yasir Y. Elamin +28 more

Simplified Molecular Classification of Lung Adenocarcinomas Based on EGFR, KRAS, and TP53 Mutations

Research Square(2020)10.21203/rs.2.12804/v4

N/A

0DataRank · unranked

0 citations

Junsheng Ma, Abha Khanna, Genevieve Lyons, Waree Rinsurongkawong, Roland Bassett +12 more

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations

BMC Cancer(2020)10.1186/s12885-020-6579-z

N/A

0DataRank · unranked

21 citations

Junsheng Ma, Abha Khanna, Genevieve Lyons, Waree Rinsurongkawong, Roland L. Bassett +12 more

LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence

The Annals of Thoracic Surgery(2020)10.1016/j.athoracsur.2020.03.114

N/A

0DataRank · unranked

18 citations

Edwin R. Parra, Jiexin Zhang, David B. Nelson, Erin M. Corsini, Pamela Villalobos +22 more

Bone morphogenetic protein 7 promotes resistance to immunotherapy

Nature Communications(2020)10.1038/s41467-020-18617-z

N/A

0DataRank · unranked

59 citations

Fatemeh Masrorpour, Cristina Ivan, Jie Zhang, Ahmed Younes, Yue Lu +13 more

Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100623

N/A

0DataRank · unranked

11 citations

Whitney E. Lewis, C. Allison Stewart, Benjamin B. Morris, Luisa M. Solis, Alejandra G. Serrano +31 more

Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.08.022

N/A

0DataRank · unranked

98 citations

John V. Heymach, Chunxiao Guo, Hari Menon, Katherine Klein, Taylor R. Cushman +19 more

Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS -Mutant Non–Small Cell Lung Cancer

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0421

N/A

0DataRank · unranked

67 citations

Ximo Pechuan-Jorge, Teng Zhou, Minh Truong, Xin Hu, Frank Rojas +22 more

Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2310

N/A

0DataRank · unranked

21 citations

Alvaro G. Paula, David Molkentine, Laura D. Hover, Monique B. Nilsson, Natalie I. Vokes +17 more

Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.04.026

N/A

0DataRank · unranked

194 citations

Marcelo V. Negrão, Seyedeh Dibaj, Runzhe Chen, Alexandre Reuben, Jadi M. Bohac +32 more

Comprehensive profiling of AML and T-cell states across disease stages in acute myeloid leukemia using spectral flow cytometry

Blood Immunology & Cellular Therapy(2025)10.1016/j.bict.2025.100004

N/A

0DataRank · unranked

4 citations

Jessica L. Root, Poonam N. Desai, Nicole Vaughn, Ferdinandos Skoulidis, Hussein A. Abbas +2 more